EMA PRIME status granted for Vertex, CRISPR Therapeutics’ gene therapy CTX001
CRISPR/Cas9 gene-edited therapy is being investigated in transfusion-dependent beta thalassemia
Read More
Tag: PRIME designation
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
